ID Analysts

Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.

Analyst Articles

Perception and reality can be two distinctly different things. For example, certain market commentators on CNBC and elsewhere have been cheering the end of the recession. Read More

We made no changes to our holdings in the past week.   Amylin Pharmaceuticals (AMLN) has given up much of its gains in the past week. While that’s disappointing, the positives for the company are numerous. We’ve got lots of time on our Amylin Pharmaceuticals (AMLN) January 12.50 call… Read More

Under the Cap

A report by the US Geological Survey (USGS) found that 25 areas inside the Arctic Circle contain about a fifth of the world’s undiscovered but recoverable oil and natural gas reserves. Read More

We’re at the mid way point of the year and the second half is likely to be every bit a thrilling as the first half. Unfortunately, we’re likely to erase much of the gains we’ve made in recent months in the second half, so we’re not necessarily talking about thrilling in a good way. Read More

Amylin Pharmaceuticals (AMLN) got a nice boost late last week on hopes that as-yet unpublished reports will voice concerns about Lantus, a competing drug from Sanofi-Aventis. It’s believed that the use of Lantus by people suffering with diabetes carries a higher risk of cancer than insulin. If true, this… Read More

It’s increasingly looking like the correction we’ve been looking for is underway. Stocks took out several important support levels with the decline yesterday, paving the way for further declines. Read More

Turning to our trades, last week we added the Research In Motion September 75 put option (RFY + UT) confident that all of the good news was baked into the share price. Sure enough, the company reported solid and offered a decent outlook on the current… Read More